China's veterinary API industry is standing at a critical crossroads in the global industrial chain. As the world's largest producer and exporter of veterinary APIs, China accounts for approximately 35% of the global market share. Behind this figure lies not only the advantages of massive output and a robust supply chain, but also the potential and challenges for China's veterinary medicine industry to move up the ranks in the global value chain.
Driven by multiple factors including the reshaping of the global economic landscape, the diversification of animal health needs, and the upgrading of China's domestic industry, the overseas expansion path of China's veterinary API industry has evolved from an optional choice into a must-answer question in 2026.
1 Industry Background: The Urgent Need for Upgrade from a Raw Material Base to a High-value Highland
China's veterinary API industry is in a critical stage of transformation from scale expansion to value enhancement. According to market data, the market size of China's veterinary APIs and intermediates had already reached a considerable scale by 2025, and the global market is projected to maintain steady growth through 2032.
The competitive landscape of the domestic veterinary industry is currently showing a distinct Matthew Effect. From 2020 to 2023, although the industry's sales revenue increased from RMB 62.095 billion to RMB 69.651 billion, the average gross profit dropped from RMB 21.998 billion to RMB 21.297 billion. Fierce internal competition has triggered a price war; for instance, the unit price of swine foot-and-mouth disease vaccines produced by Bio plummeted by 32.41% between 2020 and 2023.
International competition is also intensifying. Global animal health giants are accelerating their penetration into the domestic market, while the advancement of large-scale farming in China has driven structural changes in demand for animal health products. In 2023, the proportion of large-scale pig farming nationwide reached 68%, a significant increase from 46.9% in 2017. Large-scale farms place greater emphasis on animal disease prevention and control as well as the quality of veterinary drugs. This not only creates market space for high-quality veterinary products but also imposes higher requirements on enterprises' technical capabilities and product innovation.
2 Overseas Expansion Drivers: Dual Impetus from Internal Pressures and External Opportunities
The fundamental driving force behind Chinese veterinary API enterprises' pursuit of overseas expansion stems from the interplay between structural predicaments in the domestic market and broad opportunities in the global market.
From a domestic perspective, the industry is confronted with multiple challenges, including severe product homogenization, insufficient R&D investment intensity, low industrial concentration, as well as overcapacity of generic products alongside a shortage of high-end alternatives. The pain point of the domestic veterinary industry-being large in scale but weak in competitiveness-has compelled enterprises to explore new growth avenues.
From a global perspective, the international veterinary medicine market is witnessing diversified growth. The pet economy has emerged as a new growth engine: in 2024, the scale of China's urban pet consumption market reached RMB 300.2 billion, with pet healthcare ranking as the second-largest consumption segment. On a global scale, the pet healthcare market is even more mature; for example, the U.S. pet pharmaceutical market accounts for over 40% of the relevant market share.
Demand for veterinary drugs in emerging market countries is also growing rapidly amid the modernization of their animal husbandry sector. The development of livestock farming in regions such as Southeast Asia, South Asia, and Africa has created vast space for the export of Chinese veterinary APIs.
The restructuring of global supply chains has provided substitution opportunities for Chinese veterinary API enterprises. International animal health giants are grappling with the patent cliff and cost pressures, leading to an increased demand for cost-effective, high-quality APIs and intermediates from China. Meanwhile, the deepening of regional trade agreements has facilitated Chinese enterprises' access to specific target markets.
3 Competitive Advantage Analysis: Leap from Cost Advantage to Technological Innovation
In the process of overseas expansion, China's veterinary API industry has developed a multi-level competitive edge that ranges from basic advantages to differentiated strengths.
A complete industrial system and scale advantage form the foundation. China boasts the world's most comprehensive veterinary API industrial chain, covering everything from basic chemical raw materials to high-end and specialty APIs, with multiple industrial clusters established in North China, East China, South China, Central China and other regions. The economies of scale have brought about significant cost advantages; for example, Huisheng Biology has effectively reduced its formulation costs through the integrated layout of API production.
Continuously enhanced technological innovation capability is the key to differentiated competition. Leading enterprises like Huisheng Biology have been increasing R&D investment consistently, with a cumulative R&D expenditure of RMB 150 million since 2022. Technological innovation is reflected not only in process optimization, but also in product innovation. Domestic enterprises have been able to develop animal-specific drugs with independent intellectual property rights, such as Tylvalosin, a third-generation macrolide antibiotic exclusively for veterinary use.
The production quality system is gradually aligned with international standards. The quality management level of Chinese veterinary drug enterprises has been continuously improved, and some companies have obtained certifications from internationally authoritative bodies such as the U.S. FDA and the European EMA. For instance, the sterile formulation of Cefovecin Sodium for Injection produced by Qilu Animal Health successfully passed the pre-approval inspection conducted by the U.S. Food and Drug Administration in 2025, marking the first time that a Chinese veterinary sterile formulation enterprise has passed an on-site FDA inspection.
4 Challenges and Risks: Multiple Trials from Trade Barriers to Compliance Pressures
Despite boasting numerous advantages in overseas expansion, China's veterinary API industry still faces multiple challenges and risks that demand prudent responses.
Market access barriers and compliance requirements in the international arena represent the primary challenge. Different countries and regions vary in their registration requirements, quality standards, and residue limits for veterinary products. Mature markets such as Europe and the United States impose stringent demands on the safety and efficacy data of veterinary products, resulting in lengthy registration cycles and high costs. For example, the U.S. FDA's reorganization of its Center for Veterinary Medicine (CVM) into two independent offices has introduced uncertainties into the compliance process.
Intellectual property (IP) and patent risks cannot be overlooked. International animal health giants have established a robust patent protection network for their core products, exposing Chinese enterprises to potential risks of patent infringement lawsuits during their overseas expansion. Meanwhile, Chinese enterprises still need to enhance their awareness and capabilities regarding IP protection, particularly in terms of IP layout and rights protection in the global marketplace.
Uncertainties in the international trade environment have amplified overseas expansion risks. The rise of trade protectionism, geopolitical conflicts, exchange rate fluctuations, and other factors could all impact the international trade of veterinary APIs. Chinese veterinary API enterprises must closely monitor and flexibly respond to policy changes in their major export markets, including Southeast Asia and Europe.
Cultural differences and localization challenges should not be underestimated. Variations exist in breeding practices, disease prevention and control concepts, and veterinary usage habits across different countries and regions, requiring enterprises to conduct in-depth research and make adaptive adjustments. Brand building, marketing channels, and technical services for veterinary products all need to be tailored and optimized to align with the characteristics of local markets.
5 2026 Overseas Expansion Opportunity Assessment
Based on a comprehensive evaluation across multiple dimensions including industrial development cycle, market demand changes, technological evolution trends, and policy environment, 2026 is shaping up to be a critical strategic opportunity period for China's veterinary API industry.
The alignment between the inherent demand for industrial upgrading and the external environment has created a window of opportunity for overseas expansion. After undergoing in-depth restructuring, leading enterprises in China's domestic veterinary industry now possess product quality and technical capabilities comparable to those of their international counterparts. The global animal health market is undergoing structural transformations, with rapid growth in niche segments such as pet pharmaceuticals, aquaculture medications, and eco-friendly veterinary drugs, which provides Chinese enterprises with opportunities for differentiated competition.
Technological innovation and industrial integration are providing new momentum for overseas expansion. The application of AI technology in veterinary drug R&D is accelerating; through target prediction, compound screening and other processes, it has significantly shortened R&D cycles and reduced costs. Cutting-edge technologies such as synthetic biology and gene editing are also playing a role in veterinary API production. For example, Huisheng Biology has leveraged synthetic biology and gene editing technologies to conduct molecular engineering modification of fermentation strains, achieving an industry-leading fermentation level.
The restructuring of global supply chains has provided substitution opportunities for Chinese enterprises. International animal health giants are optimizing their supply chain layouts and seeking reliable, high-quality API suppliers, creating favorable conditions for Chinese enterprises to access high-end markets.
The deepening of regional economic cooperation has facilitated veterinary drug trade. With the implementation of regional trade agreements such as the RCEP, tariff and non-tariff barriers to veterinary product trade within the region have been gradually reduced, which is conducive to Chinese veterinary API enterprises expanding their presence in the Asian market.
6 Overseas Expansion Pathway Options
The overseas expansion pathways of Chinese veterinary API enterprises have demonstrated diversified and differentiated characteristics. Enterprises of varying scales and with distinct technological advantages can select appropriate overseas expansion strategies based on their own circumstances.
Traditional API export remains the fundamental pathway. Focusing on the export of bulk APIs and intermediates, this approach targets emerging markets such as Southeast Asia, South America, and Africa. Its advantage lies in leveraging the cost benefits of China's large-scale production to quickly capture market share. However, over-reliance on API exports may easily trap enterprises in low-price competition with limited profit margins, while also exposing them to trade barriers and anti-dumping risks.
Specialty API and CDMO models serve as the upgrading pathways. Against the backdrop of the growing global trend of veterinary drug R&D outsourcing, Chinese veterinary API enterprises can undertake custom research and manufacturing (CDMO) orders from international animal health companies by virtue of their comprehensive industrial chains and flexible production capacity. This model helps enterprises accumulate international R&D experience, upgrade technical capabilities, and establish long-term stable cooperative relationships. For instance, some leading domestic enterprises have already made breakthroughs in the veterinary CDMO sector.
Formulation product registration and independent brand globalization represent the value-added pathways. By registering formulation products in international markets, building independent brands and sales channels, enterprises can directly target end users. Although this model requires high upfront investment and a long cycle, it enables enterprises to build brand premium and secure higher profits. A case in point is that Hilewang, an anthelmintic developed by Haizheng Animal Health, was approved for marketing in the Vietnamese market, marking a substantive breakthrough in the overseas expansion of domestically-made pet medicines.
Overseas factory establishment and localized production are the deep internationalization pathways. By setting up production bases in target markets, enterprises can achieve localized production, sales, and services. This model allows for better adaptation to local market demands and circumvention of trade barriers, but it requires enterprises to have an in-depth understanding of local policies, markets, and cultures, as well as strong capital strength and risk management capabilities. Enterprises such as Huisheng Biology have already established overseas production bases in regions including Southeast Asia.
7 Key Market Analysis
The global veterinary medicine market exhibits distinct regional differences, with varying characteristics, demand dynamics, and market access requirements across different regions. Chinese enterprises need to formulate differentiated market entry strategies accordingly.
Mature Markets in Europe and AmericaFeatures: Stringent regulatory oversight, high market concentration, and strong receptiveness to innovative products.Entry Strategy: Focus on high-end specialty APIs, innovative pet pharmaceuticals, and CDMO collaborations. Priority should be given to compliance requirements set by regulatory authorities such as the FDA and EMA. Market entry can be achieved gradually through cooperation with local enterprises and acquisition of international certifications. Qilu Animal Health's success in obtaining FDA certification serves as a notable case in point.
Emerging Markets in Southeast AsiaFeatures: Rapid market growth, accelerating modernization of animal husbandry, and high price sensitivity.Entry Strategy: Prioritize the export of APIs and conventional formulations while progressively promoting independent brands. Attention should be paid to the differences in registration requirements among various countries. Market expansion can be facilitated by participating in local industry exhibitions and partnering with local distributors. For example, Tylvalosin APIs produced by Huisheng Biology have been exported to more than 20 countries and regions including Vietnam, the Philippines, and Thailand.
Markets Along the Belt and Road (B&R) InitiativeFeatures: Abundant animal husbandry resources, substantial demand in the veterinary medicine market, and strong policy support.Entry Strategy: Integrate with agricultural cooperation projects to provide comprehensive solutions. Enterprises must conduct in-depth research on local breeding characteristics and epidemic situations to develop products tailored to local needs. Exploration of an integrated output model featuring "products + technology + services" is recommended.
Differentiated overseas expansion strategies should also be adopted by enterprises of different scales.
Large-sized enterprises can implement a diversified and all-round internationalization strategy, while simultaneously laying out multiple regional markets and business models. Medium-sized enterprises can focus on specific regions or niche segments to build professional advantages. Small-sized enterprises can participate in the international division of labor by cooperating with large enterprises and concentrating on specialty APIs or intermediates.
From a raw material supply base accounting for 35% of the global market share to a technological innovator participating in the formulation of international industry standards, Chinese veterinary API enterprises are undergoing profound self-transformation. Overseas expansion is no longer an expedient measure to divert excess production capacity, but an inevitable choice for the industry to achieve value enhancement. Standards, brands and innovation are replacing costs, scale and imitation to become the key words for the internationalization of a new generation of Chinese veterinary API enterprises.
Source: Convergence Media Center, Asia Pacific Eharmony
